Characterisation of a new clinical presentation of chronic lymphocytic leukaemia: symptomatic bronchial involvement, a study from the <scp>FILO</scp> group
Morgane Nudel(Centre Hospitalier Universitaire de Lille), Charles Herbaux(Centre Hospitalier Universitaire de Lille), Stéphanie Poulain(Centre National de la Recherche Scientifique), Kamel Laribi(Centre Hospitalier du Mans), Fanny Baran‐Marszak(Sorbonne Université), Florence Cymbalista(Hôpital Avicenne), Brigitte Dreyfus, Hélène Demarquette(Ikerbasque), Cécile Tomowiak(Inserm), Stéphane Leprêtre(Normandie Université), Mathieu Wémeau(Inserm), Franck Morschhauser(Hôpital Claude Huriez), L Wemeau(Centre Hospitalier Universitaire de Lille), Romain Dubois(Centre Hospitalier Universitaire de Lille), F. Wallyn(Centre Hospitalier Universitaire de Lille), Héloïse Dapvril(Centre Hospitalier Universitaire de Lille), Jean‐Baptiste Bossard(Centre Hospitalier Universitaire de Lille), Jacques‐Olivier Bay(Centre Hospitalier Universitaire de Clermont-Ferrand), Jehan Dupuis(Inserm)
Cited by 3
Related Papers
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
|The Lancet|2018|733
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2022|718
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
|Journal of Clinical Oncology|2021|630
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|568